Atrial fibrillation (AF) is a common form of heart arrhythmia, a serious condition in which the heart beats so fast that its ...

Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in ...

For decades microtubule-targeting agents (MTAs) have been a cornerstone of cancer treatment regimens and continue to be heavily employed as backbone chemotherapy in combination with new targeted ...

A groundbreaking study published in Research (2025, DOI: 10.34133/research.0545) has elucidated the molecular mechanisms by which protein phosphatase 2A (PP2A) regulates CD8+ T cell-mediated immune ...

Recently, the research team led by Professor Zhang Zhongtao and Professor Yao Hongwei from the General Surgery Center at ...

One study showed small cell lung cancer (SCLC) tumors with higher DNA damage response (DDR) activity were initially more sensitive to chemotherapy but had worse overall survival.

New research has provided insight into the biological mechanisms that may contribute to poor outcomes in certain cases of ...

Early results show that the combination of VXM01 plus avelumab demonstrated tolerable safety in recurrent glioblastoma.

Atrial fibrillation (AF) is a common form of heart arrhythmia, a serious condition in which the heart beats so fast that its upper chambers, the atria, quiver. This irregular heartbeat can increase ...

Aura Biosciences (AURA) announced data from a completed Phase 1 window of opportunity trial of bel-sar in patients with NMIBC. These data were ...